Sol-Gel Technologies (NASDAQ:SLGL) Shares Down 0.1% – What’s Next?

Sol-Gel Technologies Ltd. (NASDAQ:SLGL)’s stock price dropped 0.1% on Tuesday . The company traded as low as $7.19 and last traded at $7.58. Approximately 2,418 shares changed hands during trading, a decline of 92% from the average daily volume of 30,800 shares. The stock had previously closed at $7.59.

Sol-Gel Technologies Price Performance

The firm’s 50 day moving average price is $6.30 and its two-hundred day moving average price is $6.86. The stock has a market cap of $21.12 million, a PE ratio of -22.29 and a beta of 1.11.

Sol-Gel Technologies (NASDAQ:SLGL) last released its quarterly earnings data on Friday, May 23rd. The company reported ($3.20) EPS for the quarter. Sol-Gel Technologies had a negative return on equity of 27.17% and a negative net margin of 81.75%. The business had revenue of $1.03 million during the quarter. Analysts anticipate that Sol-Gel Technologies Ltd. will post -0.28 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Sol-Gel Technologies stock. Raymond James Financial Inc. bought a new position in shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 108,990 shares of the company’s stock, valued at approximately $101,000. Raymond James Financial Inc. owned approximately 0.39% of Sol-Gel Technologies as of its most recent SEC filing. Institutional investors own 26.18% of the company’s stock.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.